Hormone treatments have long been used on many different illnesses and diseases. In many cases anabolic drugs have been based on testosterone which is extremely effective at triggering many different reactions in the body.
The problem is precisely in the fact that it causes many reactions. And an increased level can seriously impact organs where severe damage can be done. In many cases, the negative effects outweigh the gains made, and treatment has to be abandoned.
One area of concern is the impact on the heart where long-term use of such hormone therapies can do serious damage.
Selective Androgen Receptor Modulators (SARMs for short) have been proving a bridge to that problematic gap. In most cases they have been able to reduce the negative effects on the cardiovascular system, while there are also situations where an overall improvement has been achieved.
On this page you will find information on how hormone treatments negatively and positively affect the heart and how this has been identified in several studies.
Different Impacts On The Heart?
Over the years many studies have been performed to identify the risks of testosterone treatment. In most cases negative correlations have been found especially in men undergoing such hormone treatments.
The question always becomes whether the risk is manageable and more suitable than the problem being treated. But there have also been conflicting studies that found no such correlation.
The main risk is a higher incidence of heart attack, mainly noted in men over 65 and in those with a family history of cardiac problems.
The main physiological reasons reported are that testosterone can increase the risk of blood clotting. And this can substantially decrease the flow of blood to the heart and brain resulting in heart attacks and strokes.
The most obvious reason why SARMs don’t show this problem is that they don’t actually increase testosterone levels. They are designed to only trigger reactions in specific parts of the body where the reactions are positive and necessary.
However, some studies have even shown some positive impacts that we well highlight shortly.
What Studies Have Shown
In the vast majority of clinical trials and studies different parts of the body have been monitored. Because traditional testosterone treatment has significant negative effects, both the heart and prostate have long been a central point of attention.
This means that there is a lot of information available to identify both positive and negative impacts. In this section we’ll focus on three studies that have highlighted very specific effects.
To help make these scientific reports more readable we have stripped out technical jargon and focused on the exact parts referencing measured impacts on the heart.
Study 1 Results
This is a very extensively tested peptide that has gone through several phases of testing and trials. This research paper looked at the results from multiple trials on both animal and human subjects. The results have been very promising indeed.
The first thing noted was that the drug did not adversely affect blood pressure and heart rates. But measurements were also taken on the heart’s ability to pump blood out. This is referred to as left ventricular ejection fraction (LVEF), and when this is low, it can be an indication of a cardiac problem.
Hexarelin studies identified that positive increases in these measurements were encountered. With many heart diseases resulting in or preceded by a lower LVEF, this was then highlighted as a very important area for further study to develop more targeted drugs.
Study 2 Results
The second study of interest was conducted by the College of Pharmacy, The Ohio State University. While this study does date back to 2007, it still contains a lot of information regarding the opportunities for SARMs to be used as a highly effective androgen therapy.
The study aimed at identifying different areas and therapies where SARMs would be able to be applied. By researching clinical trial results, the authors were able to come up with several areas of medicine where such drugs had shown promising results.
One of the areas was cardiovascular benefits where one specific observed result was highlighted.
One of the main contributors to heart disease is high-density lipoprotein cholesterol (HDL-C). If you have regular medical check-ups and blood tests done, then this is something that is closely observed.
The higher the levels of cholesterol, the higher the risk of heart disease. Androgen therapies, including SARMs, have shown to lower these levels moderately. Further improvements and studies in this area were recommended as new treatment options could find very wide usage.
Study 3 Results
The final study we want to highlight was conducted by Department of Medicine, University of Tennessee Health Science Center. This research paper was specifically published to highlight the different developments of SARMs and the actions they have triggered.
By focusing on androgen receptor therapy the aim was to collect data on as many of the diverse drugs as possible. Similar to traditional testosterone treatment, the authors highlighted that earlier forms of androgen therapy negatively impacts both on the prostate and heart.
Because of the more recent developments of SARMs, previously reported negative impacts on the cardiovascular system have basically disappeared altogether. Numerous clinical trials are highlighted in this study where test subjects did not show the same cardiac symptoms as older trials using other hormone replacements.
Over the past 20 years SARMs and peptides have gained increasing attention from the pharmaceutical and medical industries. The big attraction is that they do not trigger the same effects in the prostate, liver and heart that in so many cases negate the benefits for muscle and bone tissue.
With further development and careful study it is likely that SARMs will start replacing traditional hormone treatment. More research is required as well on certain drugs that are showing signs of providing benefits to cardiac activity to identify potential heart disease treatments.